Literature DB >> 29194834

Lipid-DNAs as Solubilizers of mTHPC.

Yun Liu1, Jan Willem de Vries2, Qing Liu2, Alwin M Hartman1,3, Gerhard D Wieland4, Sebastian Wieczorek5, Hans G Börner5, Arno Wiehe4, Eric Buhler6, Marc C A Stuart1,7, Wesley R Browne8, Andreas Herrmann2, Anna K H Hirsch1,3,9.   

Abstract

Hydrophobic drug candidates require innovative formulation agents. We designed and synthesized lipid-DNA polymers containing varying numbers of hydrophobic alkyl chains. The hydrophobicity of these amphiphiles is easily tunable by introducing a defined number of alkyl chain-modified nucleotides during standard solid-phase synthesis of DNA using an automated DNA synthesizer. We observed that the resulting self-assembled micelles solubilize the poorly water-soluble drug, meta-tetra-hydroxyphenyl-chlorin (mTHPC) used in photodynamic therapy (PDT) with high loading concentrations and loading capacities. A cell viability study showed that mTHPC-loaded micelles exhibit good biocompatibility without irradiation, and high PDT efficacy upon irradiation. Lipid-DNAs provide a novel class of drug-delivery vehicle, and hybridization of DNA offers a potentially facile route for further functionalization of the drug-delivery system with, for instance, targeting or imaging moieties.
© 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.

Entities:  

Keywords:  amphiphiles; drug delivery; lipid-DNA; micelles; photodynamic therapy

Year:  2017        PMID: 29194834      PMCID: PMC5814723          DOI: 10.1002/chem.201705206

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


With the advent and fast development of high‐throughput (HTS) and ultra‐high‐throughput screening (uHTS) technologies for drug discovery over the past two decades,1 compound libraries have yielded an increasing number of potential candidates that exhibit a high affinity for their targets. A substantial number of these pharmaceutically active compounds, however, suffer from low water solubility, which hinders their development and delays market entry. Even for already marketed drugs, more than 40 % are poorly water‐soluble.2 To enable the use of these active compounds and reduce their side effects, micelles are widely used as drug‐delivery vehicles due to attractive properties such as high solubilizing efficiency, good reproducibility, simple preparation procedures and the possibility to make them stimuli‐responsive.3 Despite various amphiphilic materials being used,4 it is still a challenge to construct a biocompatible, effective and targeted micellar drug‐delivery system. Previous studies showed that amphiphilic DNA‐based copolymers self‐assemble into uniform micelles above their critical micelle concentration (CMC) and are able to accommodate drugs of interest in the hydrophobic core.5 These constructs have several advantages over those formed from synthetic polymers. First, being formed from biomacromolecules, DNA‐based micelles are more biocompatible and biodegradable and have shown no observable toxicity and little immunogenicity.6 Secondly, they can be easily synthesized by automated solid‐phase synthesis.7 Most importantly, DNA‐based micelles can be modified in a straightforward fashion by employing highly specific hybridization, which conveniently endows the system with targeting or imaging moieties.8 All these beneficial properties give them great potential to be used as targeted drug‐delivery vehicles. meta‐Tetra‐hydroxyphenylchlorin (mTHPC (1), Figure 1 a), also known as Temoporfin and Foscan (as the medicinal product),9 is a poorly water‐soluble second‐generation photosensitizer (PS) that has been widely used in PDT. It has been approved in Europe for the treatment of head and neck carcinoma.10 Conventional formulations, however, are hampered by poor water solubility and tumor‐targeting properties. As a result, novel formulations11 for mTHPC that circumvent these problems and allow for easy functionalization are required.
Figure 1

Representation of a) meta‐tetra‐hydroxyphenyl‐chlorin (mTHPC (1)); b) 5‐(dodec‐1‐ynyl)uracil deoxyribophosphoramidite (2) used in solid‐phase synthesis of lipid‐DNAs, this nucleotide building block is abbreviated as U in the corresponding sequences; c) lipid‐DNAs (, double‐stranded (ds) and ) used for the solubilization of 1; d) pristine control DNAs (11 mer, complementary 11 mer (c11 mer), double‐stranded 11 mer (ds11 mer) and 12 mer).

Representation of a) meta‐tetra‐hydroxyphenyl‐chlorin (mTHPC (1)); b) 5‐(dodec‐1‐ynyl)uracil deoxyribophosphoramidite (2) used in solid‐phase synthesis of lipid‐DNAs, this nucleotide building block is abbreviated as U in the corresponding sequences; c) lipid‐DNAs (, double‐stranded (ds) and ) used for the solubilization of 1; d) pristine control DNAs (11 mer, complementary 11 mer (c11 mer), double‐stranded 11 mer (ds11 mer) and 12 mer). Based on the considerations outlined above, nanocarriers made of lipid‐DNA amphiphiles (Figure 1 c) are excellent candidates to be used as solubilizers for poorly water‐soluble active pharmaceutical ingredients (APIs). Here, we report the successful use of lipid‐DNAs to render mTHPC water‐soluble with high drug loading capacities that (partially) retains the biological activity of the API. We synthesized lipid‐DNAs with different hydrophobicity by using the alkyl modified 5‐(dodec‐1‐ynyl)uracil phosphoramidite 2 (abbreviated U in the resulting DNA sequence, Figure 1 b) using standard solid‐phase synthesis. It was reported that lipid‐DNAs can form micellar aggregates with comparatively low CMCs and the alkyl chains did not influence the hybridization of the DNA.5b We designed and synthesized two random sequences without any self‐complementarity employing an automated DNA synthesizer. The first sequence, an 11‐mer (, 5′‐UUTGGCGTCTT‐3′), contains two modified uracil bases and the second oligonucleotide, a 12‐mer (, 5′‐UUUUUUGGATTC‐3′) (Figure 1 c), is comprised of six modified uracil bases. The CMCs are 29 and 24 μm for and , respectively. To identify the specific solubilizers for mTHPC, we screened the micelles resulting from three different types of lipid‐DNAs: single‐stranded (ss) , double‐stranded (ds) (ds) and ss (Figure 1 c). The pristine DNA counterparts with the same nucleic acid sequences, but in which the modified uracils were replaced by thymines, served as controls. This includes the ss 11 mer (5′‐TTTGGCGTCTT‐3′), ss complementary 11 mer (c11 mer, 5′‐AAGACGCCAAA‐3′), ds 11 mer (ds11 mer) and the ss 12 mer (5′‐TTTTTTGGATTC‐3′) (Figure 1 d). Samples for the screening for solubilizers contain a concentration of 50 μm both for lipid‐DNAs and controls. The formation of micellar aggregates is ensured as the concentration was set higher than the CMC of and . Incubating the aqueous solutions of DNA with the solid mTHPC ensures incorporation of mTHPC into the micelles. Centrifugation allowed for separation of the mTHPC‐loaded samples (supernatant) from the non‐solubilized mTHPC (pellet) for further characterization. We visualized and characterized the unloaded lipid‐DNA micellar aggregates by cryogenic electron microscopy (cryo‐EM) and dynamic light scattering (DLS) in terms of their size and morphology. As expected, the cryo‐EM images (Figure 2) show in the absence of mTHPC the formation of micellar aggregates with narrow size distributions and rather uniform shapes for , ds and . No obvious aggregation is visible for and ds micelles (Figure 2 a,b), while bigger aggregates form for (Figure 2 c), as confirmed by DLS displaying a characteristic slow mode of large amplitude, which might be ascribed to the hydrophobic interactions of the six alkyl chains. Interestingly, the diameter of all aggregates are within the experimental error within the same range as with six alkyl chains gives 8.2±1.8 nm (Figure 2 c), and both (Figure 2 a) and ds (Figure 2 b) have 9.8±1.0 nm and 9.9±2.0 nm, irrespectively of the two alkyl chains (Table S1). It indicates that hydrophobicity does not seem to play a critical role with respect to the micelle size, which might be due to the small size of the alkyl chains. DLS experiments performed on solutions are in agreement with cryo‐EM and give the hydrodynamic radius (R h) 10.53±1 nm and 9.54±1 nm for and ds, respectively. A slow mode of small amplitude corresponding to larger aggregates is also visible in the long‐time range of the correlation function. However, this minority population can be neglected (≈0.1 % in mass), and and ds solutions can be considered as monodisperse. Apparently, the hydrophilic DNA segments are in all cases sufficient to stabilize the polar/non‐polar interfaces nonetheless of the DNA is hybridized or not. Only for agglomeration is visible (Figure 2), which might indicate a borderline stabilization of the six alkyl chains by the six polar nucleotides.
Figure 2

Cryo‐EM images of micellar aggregates of (a), ds (b), (c) prior loading and mTHPC‐loaded micellar aggregates of (d), ds (e) and (f) (non‐stained samples and image acquisition was achieved with a 2 μm defocus; scale bar=50 nm).

Cryo‐EM images of micellar aggregates of (a), ds (b), (c) prior loading and mTHPC‐loaded micellar aggregates of (d), ds (e) and (f) (non‐stained samples and image acquisition was achieved with a 2 μm defocus; scale bar=50 nm). We screened solubilizers for mTHPC by using UV/Vis spectroscopy. Based on the absorption spectra, all mTHPC‐loaded lipid‐DNA (, ds and ) supernatants show typical absorption of mTHPC at 417 nm, which demonstrates the incorporation of mTHPC into the aqueous solutions (Figure 3). In contrast, the pristine DNAs do not show any mTHPC absorption, indicating no solubilization of the drug. The observed differences in mTHPC absorbance values can be attributed to the varied abilities to solubilize mTHPC. In this regard, the ds micelles are most efficient in incorporating the compound, followed by and finally .
Figure 3

Absorption spectra of mTHPC‐solubilized supernatants for solubilizer‐screening experiments. The inset shows the region where mTHPC exhibits an absorption maximum (417 nm).

Absorption spectra of mTHPC‐solubilized supernatants for solubilizer‐screening experiments. The inset shows the region where mTHPC exhibits an absorption maximum (417 nm). To determine the maximum loading capacities of the various lipid‐DNAs, they were incubated with a suspension of mTHPC in a mixture of H2O and EtOH, followed by lyophilization and redissolution in H2O.12 Centrifugation enabled removal of any undissolved mTHPC, affording maximum mTHPC‐loaded lipid‐DNA micelles. During the experiments, H2O and an aqueous solution of MgCl2 (Mg2+ was added to stabilize the double‐helix of the ds DNA) served as controls. We determined the loading concentrations and loading capacities by RP‐HPLC (Figure S4), adopting a method of lyophilization‐redissolution and using a calibration curve (Figure S5). The loading concentrations and loading capacities of lipid‐DNAs are presented in Table S2. As is visible, mTHPC is efficiently loaded into , ds and micellar aggregates and is found at high concentrations and corresponding loading capacities, while the controls show minimal solubilization of mTHPC. The maximum mTHPC loading concentration of ds (40.0 μm, 1:1.25 mTHPC/carrier ratio) is markedly higher than that of (31.1 μm, 1:1.61 mTHPC/carrier ratio) and (16.7 μm, 1:2.99 mTHPC/carrier ratio), which is in good agreement with the results from the solubilizer‐screening experiment. In contrast, achieved a higher loading capacity (11.7 %, w/w) than that of ds (7.8 %, w/w) due to the higher molecular weight of the double‐stranded DNA, which is a similar value to that of Pluronic® F68 (11.9 %, w/w) and conventional polymeric delivery systems.12, 13 Moreover, compared to conventional micelles, hybridization of DNA provides a facile approach for further functionalization of lipid‐DNAs with targeting groups or imaging agents. To further confirm the high loading concentrations, we recorded fluorescence‐emission spectra of the maximum mTHPC‐loaded micelles and their dilutions with equivalent volumes of EtOH (Figure S6). Abrupt increments are observed after dilution with EtOH, which illustrates the intermolecular quenching of mTHPC caused by the high concentrations inside the lipid‐DNA micelles. Cryo‐EM images of mTHPC‐loaded micelles (Figure 2 d,e,f) show the formation of micelles with a narrow size distribution and regular shape after mTHPC maximum loading. By analogy to unloaded micelles, no obvious aggregation is visible for and ds micelles, while big aggregates are formed for , as confirmed by DLS displaying a slow mode associated to these aggregates and masking the signal of the micelles in the short‐time range. As expected, the diameters of all the lipid‐DNA micelles increase after mTHPC loading. Although this trend is also observed with DLS giving R h 11.33±1 nm and 10.84±1 nm for loaded and ds, respectively, changes remain within the error bar. Interestingly, the aggregate sizes are not dramatically changing during mTHPC‐loading as only an increase in diameter of 0.8–1.3 nm could be found. Considering the significant differences in loading capacities of the three different carriers , ds and only slight hydrophobic swelling of the micellar aggregates by the mTHPC but not dramatic reorganization seems to be evident. While this might indicate the general stability of aggregates of lipid‐DNA, it also indirectly confirms a progressively loose packing of the hydrophobic alkyl chains in the core from to to ds. Hence, this observation suggests that the lipid‐DNA micelles with a less hydrophobic core or more hydrophilic corona feature bigger core spaces, enabling more efficient solubilization of mTHPC without dramatic increase of the aggregate sizes. Given that singlet oxygen (1O2) plays a key role in killing tumor cells during PDT, we evaluated the activities of mTHPC‐loaded lipid‐DNA micelles by measuring the 1O2 generation, which we monitored by near‐infrared (NIR) emission spectroscopy of 1O2 generated at 1270 nm. To facilitate the detection of 1O2, we performed all measurements in D2O, which elongates the 1O2 lifetime compared to H2O.14 For this purpose, we characterized mTHPC‐loaded micellar aggregates of and ds in D2O, by UV/Vis spectroscopy and RP‐HPLC before 1O2 generation experiments. The measured absorption spectra (Figure S7) confirm that independent of D2O, the ds solubilizes a higher amount of mTHPC than . By using RP‐HPLC (Figure S4f), we found that 12 % more mTHPC is solubilized in ds (2.8 μm) than in micelles (2.4 μm) (Table S3), which is in line with the results from the absorption spectra (Figure S7). The 1O2 phosphorescence spectra by sensitization of mTHPC‐loaded or ds micelles in D2O demonstrate that mTHPC (partially) retains its activity despite micellar solubilization (Figure 4). The observed quantum yields for singlet oxygen generation are estimated to be 0.05–0.1 for both mTHPC‐loaded or ds micelles in D2O.
Figure 4

Singlet oxygen luminescence spectra of mTHPC‐loaded and ds micelles compared to reference compound (Ru(bpy)3Cl2) in D2O.

Singlet oxygen luminescence spectra of mTHPC‐loaded and ds micelles compared to reference compound (Ru(bpy)3Cl2) in D2O. To demonstrate the PDT efficacy in vitro, we determined cell phototoxicity and dark toxicity of mTHPC (2 and 10 μm)‐loaded after 24 h incubation in six different cell lines, including human epidermoid carcinoma A253, human epithelial carcinoma A431, human oral adenosquamous carcinoma CAL27, murine hematopoiesis monocytic macrophages J774A.1, murine fibroblasts L929 and human colorectal adenocarcinoma HT29 cells, and followed by irradiation with laser light (Figure 5). As controls, we investigated cell phototoxicity and dark toxicity of empty , free mTHPC in ethanol and cells without photosensitizer following the same protocol (Figures 5 and S7). Figure S7 shows that empty micelles exhibit good biocompatibility in all cell lines, even at higher concentration (80 μm), while free mTHPC shows obvious dark toxicity and higher phototoxicity, demonstrating the PDT efficacy of mTHPC. For mTHPC‐loaded , two major conclusions can be drawn from Figure 5: (1) without irradiation, mTHPC‐loaded is silent and shows reduced dark toxicity in all cell lines in comparison to free mTHPC (Figure S7), which illustrates its good biocompatibility in vitro; (2) upon irradiation, mTHPC‐loaded becomes activated and exhibits as high phototoxicity as free mTHPC (Figure S7) in all cell lines, which demonstrates its PDT efficacy in vitro. The lack of dark toxicity against the whole panel of cells combined with the unusually high phototoxicity is remarkable.
Figure 5

Phototoxicity and dark toxicity of mTHPC (0, 2 and 10 μm)‐loaded in six different cell lines (A431, HT29, L929, J744A.1, CAL27 and A253) after 24 h incubation. The photosensitization was performed at RT with a laser at 652 nm at a dose rate of app. 50 J cm−2. The cell viability was measured with a Tecan Infinite® 200 microplate reader, at a wavelength of 490 nm.

Phototoxicity and dark toxicity of mTHPC (0, 2 and 10 μm)‐loaded in six different cell lines (A431, HT29, L929, J744A.1, CAL27 and A253) after 24 h incubation. The photosensitization was performed at RT with a laser at 652 nm at a dose rate of app. 50 J cm−2. The cell viability was measured with a Tecan Infinite® 200 microplate reader, at a wavelength of 490 nm. In summary, we have reported herein two types of lipid‐DNA polymers ( and containing varying numbers of hydrophobic alkyl chains as solubilizers of the poorly water‐soluble drug, mTHPC used in PDT. We designed the sequences and synthesized them through standard solid‐phase synthesis using an automated DNA synthesizer. Having determined their CMC values, we successfully used , ds and micelles to solubilize mTHPC with high loading concentrations and loading capacities. The ds micelles solubilize the most mTHPC, while has the highest loading capacity due to the lower molecular weight of the non‐hybridized DNA section. We conclude that lipid‐DNA micelles with a less hydrophobic core or more hydrophilic corona result in micellar aggregates and less compact core packings, which leads to enhanced solubilization of mTHPC. In addition, the generated phosphorescence demonstrates that mTHPC (partially) remains active in D2O. Finally, a cell viability study showed that mTHPC‐loaded shows excellent biocompatibility without irradiation, and very high PDT efficacy upon irradiation. Our work illustrates the successful use of lipid‐DNA micelles to solubilize mTHPC with high loading capacities while (partially) retaining the biological activity of the API. Interestingly, the size and morphology of the micelles are related to the hydrophobicity of the corresponding lipid‐DNAs, which can be fine‐tuned by hybridization with the complementary strand or altering the number of incorporated modified uracil nucleotides. Thus, the present results offer a basis for the rational design of a novel class of drug‐delivery vehicle based on lipid‐DNAs. Notably, hybridization offers a facile route for further functionalization of the drug‐delivery system, allowing adding moieties such as targeting groups or imaging reagents by hybridization. Therefore, our lipid‐DNA micellar drug‐delivery system holds great potential for further development and application in the biomedical field.

Conflict of interest

The authors declare no conflict of interest. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re‐organized for online delivery, but are not copy‐edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Supplementary Click here for additional data file.
  22 in total

Review 1.  High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery.

Authors:  R E White
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

Review 2.  Pharmaceutical applications of cyclodextrins: basic science and product development.

Authors:  Thorsteinn Loftsson; Marcus E Brewster
Journal:  J Pharm Pharmacol       Date:  2010-11       Impact factor: 3.765

3.  Tunable hydrophobicity in DNA micelles: design, synthesis, and characterization of a new family of DNA amphiphiles.

Authors:  Milena Anaya; Minseok Kwak; Andrew J Musser; Klaus Müllen; Andreas Herrmann
Journal:  Chemistry       Date:  2010-11-15       Impact factor: 5.236

4.  Exploiting specific interactions toward next-generation polymeric drug transporters.

Authors:  Sebastian Wieczorek; Eberhard Krause; Steffen Hackbarth; Beate Röder; Anna K H Hirsch; Hans G Börner
Journal:  J Am Chem Soc       Date:  2013-01-23       Impact factor: 15.419

5.  Controlled drug release to cancer cells from modular one-photon visible light-responsive micellar system.

Authors:  Saemi O Poelma; Seung Soo Oh; Sameh Helmy; Abigail S Knight; G Leslie Burnett; H Tom Soh; Craig J Hawker; Javier Read de Alaniz
Journal:  Chem Commun (Camb)       Date:  2016-08-18       Impact factor: 6.222

Review 6.  Photo-responsive polymeric micelles.

Authors:  Yu Huang; Ruijiao Dong; Xinyuan Zhu; Deyue Yan
Journal:  Soft Matter       Date:  2014-09-07       Impact factor: 3.679

Review 7.  Temoporfin (Foscan®, 5,10,15,20-tetra(m-hydroxyphenyl)chlorin)--a second-generation photosensitizer.

Authors:  Mathias O Senge; Johan C Brandt
Journal:  Photochem Photobiol       Date:  2011-09-19       Impact factor: 3.421

Review 8.  Amphiphilic poly(amino acid) based micelles applied to drug delivery: the in vitro and in vivo challenges and the corresponding potential strategies.

Authors:  Helin Xu; Qing Yao; Cuifang Cai; Jinxin Gou; Yu Zhang; Haijun Zhong; Xing Tang
Journal:  J Control Release       Date:  2014-12-12       Impact factor: 9.776

Review 9.  Targeted drug delivery by thermally responsive polymers.

Authors:  Ashutosh Chilkoti; Matthew R Dreher; Dan E Meyer; Drazen Raucher
Journal:  Adv Drug Deliv Rev       Date:  2002-09-13       Impact factor: 15.470

10.  DNA micelle flares for intracellular mRNA imaging and gene therapy.

Authors:  Tao Chen; Cuichen Sam Wu; Elizabeth Jimenez; Zhi Zhu; Joshua G Dajac; Mingxu You; Da Han; Xiaobing Zhang; Weihong Tan
Journal:  Angew Chem Int Ed Engl       Date:  2013-01-14       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.